Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Postoperative adjuvant therapy for cervical cancer based on minimal residual disease

Phase 2 trial that assigns adjuvant treatment from risk group and MRD status. The registry primary outcome is 3-year disease-free survival. ClinicalTrials.gov lists the study as recruiting.

Suzhou Municipal Hospital